Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Show other versions (1)

BACKGROUND: We report clinical safety and biochemical efficacy from a dose-ranging study of intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer (PMO) in patients with Duchenne muscular dystrophy. METHOD: We undertook an open-label, phase 2, dose-escalation study (0·5, 1·0, 2·0...

Full description

Bibliographic Details
Main Authors:	Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K, Abbs, S, Garralda, M, Bourke, J, Wells, D, Dickson, G, Wood, M, Wilton, S, Straub, V, Kole, R, Shrewsbury, S, Sewry, C, Morgan, J, Bushby, K, Muntoni, F
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study
by: Cirak, S, et al.
Published: (2011)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
by: Kinali, M, et al.
Published: (2009)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
by: Goyenvalle, A, et al.
Published: (2010)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
by: Goyenvalle, A, et al.
Published: (2010)

Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
by: Li, Chengxi, et al.
Published: (2021)

Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency
by: Yin, HF, et al.
Published: (2016)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
by: Frank, DE, et al.
Published: (2020)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
by: Yokota, T, et al.
Published: (2012)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
by: Betts, C, et al.
Published: (2014)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
by: Janghra, N, et al.
Published: (2016)

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
by: Lu, Q, et al.
Published: (2003)

Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice
by: Forand, A, et al.
Published: (2020)

Muscle X-inactivation patterns and dystrophin expression in Duchenne muscular dystrophy carriers.
by: Matthews, P, et al.
Published: (1995)

Use of antisense-mediated exon skipping to generate dystrophin in muscles of the mdx dystrophic mouse
by: Lu, Q, et al.
Published: (2004)

Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.
by: Nowak, K, et al.
Published: (2004)

The Duchenne and Becker muscular dystrophy gene and protein product dystrophin
by: Monaco, A
Published: (1989)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019)

Dystrophin, the protein product of the Duchenne/Becker muscular dystrophy gene.
by: Monaco, A
Published: (1989)

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
by: Yin, H, et al.
Published: (2009)

Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy.
by: Krag, T, et al.
Published: (2001)

Micro-dystrophin genes bring hope of an effective therapy for duchenne muscular dystrophy
by: Davies, K, et al.
Published: (2019)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
by: Griffin, J, et al.
Published: (2002)

Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
by: Straub, V, et al.
Published: (2016)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
by: Aoki, Y, et al.
Published: (2012)

Absence of the dystrophin protein in Duchenne muscular dystrophy: effects on transcriptome, proteome and microRNA secretome
by: van Westering, T
Published: (2018)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2010)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
by: Aoki, Y, et al.
Published: (2011)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2011)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
by: Goyenvalle, A, et al.
Published: (2009)

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
by: Wang, Q, et al.
Published: (2010)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
by: Blain, A, et al.
Published: (2018)

Dystrophin gene analysis in Duchenne/Becker dystrophy in a Malaysian population using multiplex polymerase chain reaction
by: Tan, J., et al.
Published: (2010)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
by: Perkins, K, et al.
Published: (2018)

RNA-seq analysis of an antisense sequence optimized for exon skipping in Duchenne patients reveals no off-target effect
by: Domenger, C, et al.
Published: (2017)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2012)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
by: Goyenvalle, A, et al.
Published: (2012)

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
by: Aoki, Y, et al.
Published: (2010)

Guidelines for morpholino use in zebrafish
by: Stainier, Didier Y. R., et al.
Published: (2018)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
by: Goyenvalle, A, et al.
Published: (2011)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
by: Betts, C, et al.
Published: (2018)